drugset / Trial / NCT00003025

Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer

NCT00003025

Phase 1 Completed 16 enrolled Memorial Sloan Kettering Cancer Center
Treatment

Summary

RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells. Combining vaccine therapy with surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients with stage I or stage II pancreatic cancer that has been surgically removed.

Timeline

Start
1997-03
Primary completion
2002-07
Completion
2002-07

Publications

  • Results Maki RG, Lewis JJ, Janetzki S, et al.: Phase I study of HSPPC-96 (oncophage®) vaccine in patients with completely resected pancreatic adenocarcinoma. [Abstract] European Journal of Cancer Supplements 1 (5): A-48, S19, 2003.

Drugs

EvaluationDrugModalityDoseRoute
Subject vitespen Vaccine Subcutaneous